| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Tropisetron (also known as ICS 205-930) is a novel, potent and selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist, used to treat nausea and vomiting following chemotherapy. Tropisetron binds with great affinity to both 5HT3R and th α7 nAChR. With respect to the other nicotinic subtypes tested, tropisetron has very little affinity.
| Targets |
5-HT3 receptor( Ki = 5.3 nM ); α7 nAChR ( Ki = 6.9 nM )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Cell Assay |
In either case, p65, JNK, ERK1 + 2, p38, and IκBα proteins were stimulated in Jurkat cells (1 × 106 cells/ml) using TNFα (2 ng/ml) or PMA (20 ng/ml) plus ionomycin (0.5 ug/ml) in the presence or absence of tropisetron. Following a PBS wash, proteins were extracted using 50 μl of lysis buffer that contained 0.5% NP-40. The Bradford assay was used to determine the protein concentration. After boiling 30 μg of proteins in Laemmli buffer, the proteins were electrophoresed in 10% SDS/polyacrylamide gels.
|
|
| Animal Protocol |
Male albino mice
3 mg/kg i.p. |
|
| References |
| Molecular Formula |
C17H20N2O2
|
|---|---|
| Molecular Weight |
284.3529
|
| Exact Mass |
284.15
|
| Elemental Analysis |
C, 71.81; H, 7.09; N, 9.85; O, 11.25
|
| CAS # |
89565-68-4
|
| Related CAS # |
Tropisetron Hydrochloride; 105826-92-4
|
| Appearance |
Solid powder
|
| SMILES |
CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43
|
| InChi Key |
ZNRGQMMCGHDTEI-FUNVUKJBSA-N
|
| InChi Code |
InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13?
|
| Chemical Name |
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate
|
| Synonyms |
ICS 205930; ICF 205-930; Tropisetron
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~10 mg/mL (~35.2 mM)
Water: ~56 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5168 mL | 17.5840 mL | 35.1679 mL | |
| 5 mM | 0.7034 mL | 3.5168 mL | 7.0336 mL | |
| 10 mM | 0.3517 mL | 1.7584 mL | 3.5168 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05564286 | Recruiting | Drug: Fosaprepitant Drug: tropisetron |
Cervical Cancer Antiemetic |
Shantou University Medical College |
July 1, 2021 | Phase 3 |
| NCT05533281 | Recruiting | Drug: tropisetron Drug: metoclopramide |
Nausea and Vomiting | The Second Affiliated Hospital of Chongqing Medical University |
September 15, 2022 | Early Phase 1 |
| NCT05242874 | Active Recruiting |
Drug: Fosaprepitant , Tropisetron and Olanzapine Drug: Fosaprepitant , Tropisetron, Dexamethasone and Olanzapine |
Chemotherapy-induced Nausea and Vomiting |
Henan Cancer Hospital | January 1, 2022 | Phase 3 |
| NCT04817189 | Recruiting | Drug: NEPA (300mg netupitant /0.5mg palonosetron) Drug: Dexamethasone, 8 mg (oral) or equivalent IV dose |
Chemotherapy-induced Nausea and Vomiting |
Helsinn Healthcare SA | February 1, 2021 | Phase 4 |
| NCT00435370 | Completed | Drug: Tropisetron Drug: Placebo |
Smoking Cessation Schizophrenia |
Baylor College of Medicine | November 2006 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
